Allogene Therapeutics ALLO Cash Flow Statement
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| -$190.89M+25.9% | -$257.59M+21.3% | -$327.27M+3.9% | -$340.41M-86.9% | ||
| $12.36M-9.4% | $13.64M-3.9% | $14.2M-0.7% | $14.3M+36.7% | ||
| $37.64M-27.3% | $51.74M-21.5% | $65.95M-21.1% | $83.6M+3.4% | ||
| —— | -$537K+92.8% | -$7.5M-254% | $4.87M+735% | ||
| —— | —— | —— | —— | ||
| —— | -$4.28M-394% | $1.46M-60.1% | $3.65M— | ||
| $1.14M+338% | $259K— | —— | -$1.88M— | ||
| -$7.5M-19.0% | -$6.31M— | —— | —— | ||
| -$149.25M+25.5% | -$200.3M+15.7% | -$237.73M-7.8% | -$220.52M-19.3% | ||
| $386K-44.4% | $694K-54.2% | $1.52M-70.8% | $5.19M-75.8% | ||
| $138.26M-61.8% | $361.48M-17.6% | $438.63M+76.8% | $248.11M-52.8% | ||
| $0— | —— | —— | $0— | ||
| $95.56M— | —— | —— | $106.16M-35.1% | ||
| —— | $1.54M-98.3% | $91.11M— | $0— | ||
| $30.16M-74.2% | $116.68M+21.9% | $95.7M+3,144% | $2.95M-75.3% | ||
| —— | —— | —— | —— | ||
| —— | —— | —— | —— | ||
| $2.72M-87.8% | $22.32M— | —— | —— | ||
| -$7.5M-19.0% | -$6.31M— | —— | —— | ||
| $1.14M+338% | $259K— | —— | -$1.88M— | ||
| -$3.24M— | —— | —— | -$2.52M+21.3% | ||
| $4.22M-49.4% | $8.35M+22.6% | $6.81M+336% | -$2.89M+58.4% | ||
| $12.92M+3.3% | $12.51M+3.8% | $12.05M+26.3% | $9.54M+58.7% | ||
| $234.2M-45.8% | $432.46M-27.7% | $597.81M+66.3% | $359.46M-50.7% | ||
| —— | —— | —— | —— | ||
| $0— | —— | $2.09M+327% | $489K-94.1% | ||
| —— | —— | —— | —— | ||
| —— | —— | $0— | —— | ||
| -$7.5M-19.0% | -$6.31M— | —— | —— | ||
| $4.36M-17.3% | $5.26M-20.8% | $6.64M+173% | $2.43M-7.2% | ||
| -$149.63M+25.6% | -$200.99M+16.0% | -$239.25M-6.0% | -$225.71M-9.4% | ||
| -$149.63M+25.6% | -$200.99M+16.0% | -$239.25M-6.0% | -$225.71M-9.4% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Allogene Therapeutics generate?
- Allogene Therapeutics (ALLO) generated -$109.2M in operating cash flow over the trailing twelve months.
- What is Allogene Therapeutics's free cash flow?
- After $296.0K of capital expenditures, Allogene Therapeutics's free cash flow was -$109.5M over the trailing twelve months, up 44.7% year over year.
- Where does Allogene Therapeutics's cash flow data come from?
- Every line is extracted from Allogene Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.